Alcon Terminates Merger Agreement with STAAR Surgical, Focuses on New Product Launches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Newsfilter
- Merger Agreement Termination: Alcon announced the termination of its merger agreement with STAAR Surgical, reflecting a disciplined approach to price and risk management, although this decision may impact future market expansion efforts.
- Strategic Focus: CEO David J. Endicott emphasized that despite the merger's failure, Alcon will continue to concentrate on its refractive surgery strategy, particularly the newly launched wavelight®plus product, aimed at enhancing competitiveness in the LASIK market.
- Product Launch Plans: Alcon plans to globally launch over 10 major products in 2025 across its surgical and vision care segments, with these innovations expected to significantly improve treatment outcomes for eye care disorders and help patients see better worldwide.
- Market Impact: Despite the merger setback, Alcon remains committed to enhancing market share through innovative products, which is anticipated to positively influence its leadership position in the eye care industry.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALC is 91.11 USD with a low forecast of 75.18 USD and a high forecast of 112.77 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 80.290
Low
75.18
Averages
91.11
High
112.77
Current: 80.290
Low
75.18
Averages
91.11
High
112.77
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
